Metformin for Longevity and Sarcopenia: A Therapeutic Paradox in Aging - PubMed
3 hours ago
- #metformin
- #aging
- #sarcopenia
- Metformin is a first-line antidiabetic drug with potential geroprotective benefits.
- It improves metabolic homeostasis, reduces oxidative stress, and attenuates chronic inflammation.
- Observational studies link metformin use to lower sarcopenia prevalence, especially in insulin-resistant older adults.
- Randomized trials show metformin may hinder muscle hypertrophy and protein synthesis in healthy older adults.
- This paradox suggests metformin's effects depend on metabolic context: beneficial in frail individuals but limiting in active ones.
- Precision geropharmacology is needed to balance metabolic longevity with musculoskeletal health.